Highly Parallel AIDS Assays Using A Microfluidic Flow Cell Array Integrated with

描述(申请人提供)：该项目的最终目标是开发一个用于高通量检测患者样本的HIV特异性血清抗体的多重标记免费平台。为了帮助Wasatch Microfludics实现这一最终目标，该提案将探讨通过将新型微流控斑点技术应用于现有的表面等离子体共振(SPR)阵列平台，对多种HIV蛋白的血清抗体进行高通量无标记检测的可行性。具体地说，微流控流动细胞阵列将适用于处理诸如血浆、血清和细胞裂解物之类的“真实世界”样本。Flow细胞阵列将有48个通道，并针对一系列旨在支持正在进行的非人类灵长类动物临床前试验以及人类艾滋病毒疫苗试验的点。发展一种低成本、高通量、多重检测方法来评估疫苗接种后体液免疫反应的发展，对于全面的免疫监测是至关重要的。公共卫生相关性：这项提案的成功完成将极大地提高在药物发现和蛋白质组研究中进行基于SPR的多重分析的能力。在更大的范围内，这将通过显著提高无标签筛查的吞吐量，改进诊断工具并减少药物开发的成本和时间。

DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a multiplex label free platform for high-throughput HIV specific serum antibody detection of patient samples. To help Wasatch Microfludics reach this ultimate goal, this proposal will address the feasibility of performing high throughput label free detection of serum antibodies to a variety of HIV proteins through the application of a novel microfluidic spotting technology to available Surface Plasmon Resonance (SPR) array platforms. Specifically, a microfluidic flow cell array will be adapted for work with "real world" samples such as plasma, serum, and cell lysates. The flow cell array will have 48 channels and address an array of spots designed to support ongoing pre- clinical trials in non-human primates as well as HIV vaccine trials in humans. The development of a low cost, high throughput, multiplex assay to assess the development of humoral immune responses following vaccine administration is essential for comprehensive immunomonitoring. PUBLIC HEALTH RELEVANCE: The successful completion of this proposal will create a dramatic improvement in the ability to conduct multiplex SPR-based assays in drug discovery and proteomic research. On a greater scale, this will lead to improved diagnostic tools and reductions in the cost and time of drug development, by significantly improving the throughput of label free screening.